RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Drug class review on second generation antidepressants
Final report [Internet]
Gartlehner, G., Hansen, RA., & Kahwati, L. C. (2006). Drug class review on second generation antidepressants: Final report [Internet]. Oregon Health & Science University. https://www.ncbi.nlm.nih.gov/books/NBK10326/
Axis I psychiatric disorders such as depressive disorder, anxiety disorder, adjustment disorder, and premenstrual disorders are serious disabling illnesses. Newer treatments for these disorders include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and other second-generation drugs. The purpose of this review is to help policymakers and clinicians make informed choices about the use of SSRIs and newer antidepressants.
